Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2021

01-01-2021 | Images

Metastatic Angiosarcoma of Bone Marrow Mimicking a Pleomorphic Myeloma

Authors: Shruti Mishra, Ashutosh Panigrahi, Amit Kumar Adhya

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2021

Login to get access

Excerpt

A 55-year-old female presented with pain and swelling of the abdomen. On investigation, she was found to have ascites, multiple sclerotic lesions in the vertebra, ribs, hip bone, and femur, multiple enhancing lesions in bilateral liver lobes with hepatomegaly and splenomegaly. Her hemoglobin was 7.1 gm/dL, total leucocyte count 2.88 × 109/L, total platelet count was 13 × 109/L. The bone marrow aspirate showed large clusters of tumor cells. The tumor cells were large, round to spindle-shaped with central to eccentrically placed nuclei with prominent nucleoli and abundant gray-blue cytoplasm (Fig. 1a, b). The morphology on the aspirate smears resembled a pleomorphic myeloma. The bone marrow biopsy showed total replacement of the marrow spaces by a tumor composed of spindle to round pleomorphic cells arranged in the form of variable-sized vascular spaces and solid sheets (Fig. 1c, d). The tumor cells were immunopositive for CD31, CD34, (Fig. 1e, f) Vimentin, and BCL-2 and immunonegative for Pan-cytokeratin, S-100, HMB-45, Synaptophysin, LCA, CD38, Desmin, SMA and EMA. A diagnosis of metastatic angiosarcoma was made.
Metadata
Title
Metastatic Angiosarcoma of Bone Marrow Mimicking a Pleomorphic Myeloma
Authors
Shruti Mishra
Ashutosh Panigrahi
Amit Kumar Adhya
Publication date
01-01-2021
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01344-2

Other articles of this Issue 1/2021

Indian Journal of Hematology and Blood Transfusion 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine